HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 04-22-2015, 12:31 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Lightbulb another Achilles heel for her2+ breast cancer?

Two recent papers shed light on how breast cancer cells avoid cell death
William G. Gilroy April 17, 2015

Two new papers from the lab of Zach Schafer, Coleman Assistant Professor of Cancer Biology at the University of Notre Dame, offer insights into how breast cancer cells avoid anoikis, which is cell death induced by detachment from the extracellular matrix (ECM).

“Metastasis, the spread of cancer cells from the primary tumor site to distant sites in the body, is responsible for in excess of 90 percent of cancer deaths,” Schafer said. “In order for cancer cells to metastasize, they must survive the trip from the primary tumor to a secondary site. A significant barrier to cancer cell survival is the process of anoikis. Cancer cells are periodically exposed to ECM detachment during metastasis, and thus it is critically important to better understand at the molecular level how cancer cells block anoikis. If we could better understand these molecular mechanisms, we could design novel chemotherapeutics aimed at inducing anoikis and thereby blocking metastasis.”

The research described in the first paper describes how Schafer’s lab group discovered that ErbB2, an oncogene overexpressed in approximately 30 percent of breast cancer patients, can block the induction of anoikis by causing multicellular aggregation. This multicellular aggregation results in stabilization of another protein, EGFR, that can signal in ECM-detached breast cancer cells to block anoikis.

“These findings suggest that finding ways to break up multicellular aggregates might be an effective strategy to eliminate metastasizing breast cancer cells,” Schafer said. “In addition, targeting the EGFR protein has not been particularly effective in breast cancer patients, but our studies suggest that this may be a useful strategy to eliminate ECM-detached cancer cells.”

The research was led by Raju Rayavarapu, a doctoral candidate in the Department of Biological Sciences under Schafer’s supervision. Melissa Shaw, a junior biological sciences major, was a contributing author, and two former Notre Dame undergraduates, Brendan Heiden and Nicholas Pagani, also were co-authors. Additionally, Sydney Shuff, a high school senior at Concord High School in Elkhart, was a co-author and Siyuan Zhang, Nancy Dee Assistant Professor of Cancer Research at the Harper Cancer Research Institute, collaborated on the work.

The paper was featured as the cover article of the Journal of Biological Chemistry and can be accessed here. Kimbra Turner, a doctoral student in biological sciences at Notre Dame, designed the cover art.


This second part is for those with IBC:

The second paper focused on understanding anoikis inhibition in inflammatory breast cancer, a rare subtype of breast cancer.

“Inflammatory breast cancer (IBC) has a very unique disease progression that causes women to be frequently misdiagnosed,” Schafer said. “Instead of starting as a lump in the breast, IBC manifests as reddened skin that is often mistaken for an infection. In fact, this reddening is due to IBC cancer cells lodging in the lymphatic vessels under the skin. It is inherently aggressive and the fact that it is frequently misdiagnosed exacerbates problems for the patient. Prognosis for women with IBC is often poor.”

In this study, the researchers discovered a unique molecular mechanism used by IBC cells to block anoikis.

“Unlike what we observed in other breast cancer cells, we have found that IBC cells have elevated levels of the protein Bim-EL," Schafer said. “This protein typically would either be eliminated rapidly or, conversely, localized in the cell to cause cell death. However, in IBC cells, this protein binds to two other proteins (Beclin-1 and LC8) in a fashion that prevents it from causing cell death. This appears to be a unique mechanism utilized by IBC cells to block anoikis.”

The fact that Bim-EL, a protein that can cause cells to die, is present in high levels in IBC cells represents an attractive therapeutic target. Approaches aimed at freeing Bim-EL from the complex with Beclin-1 and LC8 may be effective in specifically eliminating IBC cells.

The research in Schafer’s lab was led by Cassandra Buchheit, a recent graduate of the Notre Dame’s doctoral program in biological sciences. Kelsey Weigel, a doctoral candidate in biological sciences and a Berry Family Foundation Fellow in Advanced Diagnostics and Therapeutics, and former undergraduate students Brittany Angarola and Allison Steiner were also co-authors on the manuscript. The research effort was initiated due to support from Notre Dame’s Boler-Parseghian Center for Rare and Neglected Diseases.

The paper appeared in the journal Cell Death and Differentiation.

Contact: Zachary T. Schafer, 574-631-0875, zschafe1@nd.edu
Lani is offline   Reply With Quote
Old 04-23-2015, 04:26 PM   #2
suzan w
Senior Member
 
suzan w's Avatar
 
Join Date: Sep 2005
Location: Naples FL
Posts: 1,744
Re: another Achilles heel for her2+ breast cancer?

Anoikis=good??
__________________
Suzan W.
age 54 at diagnosis
5/05 suspicious mammogram-left breast
5/05 biopsy-invasive lobular carcinoma with LCIS,8mm tumor,stage 1 grade 2, ER+ PR+ Her2+++
6/14/05 bilateral mastectomy, node neg. all scans neg.
Oncotype DX-high risk
8/05-10/05 4 rounds A/C
10/05 -10/06 1 yr. herceptin
arimidex-5 years
2/14/08 started daily self administered injections..FORTEO for severe osteoporosis
7/28/09 BRCA 1 negative BRCA2 POSITIVE
8/17/09 prophylactic salpingo-oophorectomy
10/15/10 last FORTEOinjection
RECLAST infusion(ostoeporosis)
6/14/10 5 year cancerversary!
8/2010-18%increase in bone density!
no further treatments
Oncologist says, "Go do the Happy Dance"
I say,"What a long strange trip its been"
'One day at a time'
6-14-2015. 10 YEAR CANCERVERSARY!
7-16 to 9-16. Extensive (and expensive) dental work done to save teeth. Damage from osteoporosis and chemo and long term bisphosphonate use
6-14-16. 11 YEAR CANCERVERSARY!!
7-20-16 Prolia injection for severe osteoporosis
2 days later, massive hive outbreak. This led to an eventual dx of Chronic Ideopathic Urticaria, an auto-immune disease from HELL.
6-14-17 12 YEAR CANCERVERSARY!!
still suffering from CIU. 4 hospitilizations in the past year

as of today, 10-31-17 in remission from CIU and still, CANCER FREE!!!
6-14-18 13 YEAR CANCERVERSARY!! NED!!
suzan w is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:47 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter